Citius Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Dec 23, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 23, 2025
CTXR$0.53-3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| 2025 | 2024 | |
|---|---|---|
| Revenues | $— | $— |
| Operating Expenses: | ||
| Research and development | 9,156,474 | 11,906,601 |
| General and administrative | 18,532,843 | 18,249,402 |
| Stock-based compensation – general and administrative | 10,836,291 | 11,839,678 |
| Total Operating Expenses | 38,525,608 | 41,995,681 |
| Operating Loss | (38,525,608) | (41,995,681) |
| Other Income (Expense): | ||
| Interest income | 110,081 | 758,000 |
| Interest expense | (267,782) | — |
| Gain on sale of New Jersey net operating losses | — | 2,387,842 |
| Total Other Income (Expense), Net | (157,701) | 3,145,842 |
| Loss before Income Taxes | (38,683,309) | (38,849,839) |
| Income tax expense | 1,056,960 | 576,000 |
| Net Loss | (39,740,269) | (39,425,839) |
| Net loss attributable to non-controlling interest | 2,306,358 | 287,000 |
| Deemed dividend on warrant extension | — | (1,047,312) |
| Net Loss Applicable to Common Stockholders | $(37,433,911) | (40,186,151) |
| Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted | $(3.38) | (5.97) |
| Weighted Average Common Shares Outstanding | ||
| Basic and diluted | 11,065,225 | 6,726,999 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.